Now in its third year, Pharma Sustainability Integrates brings together experts, leaders, academics and policy makers from across industry and healthcare to discuss the challenges and opportunities related to reducing the environmental impact of the industry and the wider healthcare system. Featuring keynote presentations, fireside chats and interactive debate-led panel sessions, the agenda will cover policy, strategy, innovation and how industry can play its part in reducing its own Carbon footprint and that of the wider healthcare eco-system.
This year we will discuss:
How are the sustainability policies and expectations of government, investors, customers and employees shaping the future of pharma?
How can innovative technology help to reduce the carbon footprint of the entire pharmaceutical supply chain, from manufacturing to patient delivery?
As a ‘scope 3’ source of Carbon for Healthcare systems, how can the sector partner to reduce the overall environmental impact of Healthcare?
AstraZeneca UK
Country President
Tom is President of AstraZeneca UK, the UK’s leading biopharmaceutical company. He became President in March 2020, following 20 years working in senior roles across Asia, Europe, and the US. Tom is passionate about making a difference to people’s lives through groundbreaking science and new medicines, through working in partnership to tackle pressing health challenges, and accelerating the UK as a global centre of excellence for life sciences. Prior to joining AZ, Tom spent a decade in consulting and venture capital, and a year in the British Army.
Scottish Government Health & IoD Scotland
Head of Circular Economy Programme & IoD Scotland Lead Sustainability Ambassador
Future Biogas
Chief Executive Officer
Philipp Lukas is the founder and CEO of Future Biogas – one of the largest producers of biomethane in the UK.
Following investment from 3i Infrastructure plc, Future Biogas is working to reshape the biogas industry, directly decarbonising agriculture and industry by making high-quality, unsubsidised green gas from sustainably grown inputs.
Philipp sits on the board of the European Biogas Association (EBA) and co-chairs the EU Commission’s Biomethane Industrial Partnership (BIP).
Sustainable Healthcare Coalition
Chair
As a leading expert in sustainability and health, I currently serve as Chair of the Sustainable Healthcare Coalition a pioneering organisation that brings together partners to advance sustainable healthcare.
Additionally, I act as an independent expert advisor and board member for various national and global organisations, providing valuable insight and guidance on well-being and sustainability.
I’m passionate about reframing thinking and have a track record of developing innovative strategies and programmes at the heart of business and government.
My background includes senior roles in the UK Government as Deputy Chief Medical Officer and Director General, in the World Health Organisation as Director of Chronic Disease and Health Promotion, and in the private sector, as Bupa’s Chief Wellbeing Officer and as a Director in PwC’s health and sustainability teams.
I am a visiting Professor at UCL and a Senior Associate at Cambridge Institute for Sustainability Leadership and have served on various boards including British Land’s Sustainability Advisory Panel, Marks and Spencer’s Sustainable Retail Advisory Board, and Business in the Community’s Wellbeing Leadership Team.
Bayer
Head of Sustainability & Public Affairs UK & Ireland
Andy spent 17 years in senior Sales leadership and Commercial roles within FMCG, Skincare and Pharma, he then made a career pivot over 3 years ago to proactively supercharge and lead the Sustainability agenda at Bayer UK & Ireland. Andy works across the full spectrum of Sustainability, covering Policy, ESG & Non-Financial Disclosures, Carbon Footprinting, Impact Valuation, Life Cycle Assessments, Employee Engagement and many more.
Andy voices how driving a culture of sustainability and incorporating it into everyday roles and responsibilities is essential to delivering a net zero agenda as well as the powerful role story telling plays in supporting organisations transformation from Board level all the way through the business.
GSK
Director, Global Sustainability Policy
Rachel leads GSK’s global approach to environmental sustainability policy, supporting the company’s ambition for a net zero, nature positive, healthier planet. Rachel has worked in policy and government affairs roles across the pharmaceutical sector for over 10 years, and has previously worked on environmental policy, including in the European parliament and in the water sector.
AstraZeneca UK
Country President
Tom is President of AstraZeneca UK, the UK’s leading biopharmaceutical company. He became President in March 2020, following 20 years working in senior roles across Asia, Europe, and the US. Tom is passionate about making a difference to people’s lives through groundbreaking science and new medicines, through working in partnership to tackle pressing health challenges, and accelerating the UK as a global centre of excellence for life sciences. Prior to joining AZ, Tom spent a decade in consulting and venture capital, and a year in the British Army.
CPI, Medicines Manufacturing Innovation Centre
Managing Director, Pharma, Healthtech and Quality
Prior to joining CPI Dave worked for GSK. He joined the company in 1992 as a PhD Chemist from Glasgow University. He has over 20 years’ experience at GSK carrying out a number of Technical, Compliance and Manufacturing leadership roles. In 1997 he moved to Irvine to take up a lead chemist role before coming Quality Control Manager in 1998. He joined the site leadership team in 2001 to run Technical Development before moving to manufacturing as Actives Production Director in 2005.
During this time he completed a Masters degree in Manufacturing Leadership at Cambridge University. In 2007 he moved to GSK House to work on a central network re-structuring project before becoming Site Director at Montrose in October 2008. At Montrose, he led the transformation of the site to manufacture over 12 products for GSK including a major investment programme. In 2011 he was appointed VP Primary Supply Chain with responsibility for global Active Pharmaceutical Ingredients (API) manufacture and supply, a network of GMS sites across the world including facilities in Asia and Europe. In 2017 he was appointed VP Head of GMS Strategy with responsibility for manufacturing strategy, deployment of strategic programmes, performance management and advocacy.
He plays an active role with a number of Governments and is currently co-chair of the Life Sciences Scotland Industry Leadership Group.
GSK
Director, Global Sustainability Policy
Rachel leads GSK’s global approach to environmental sustainability policy, supporting the company’s ambition for a net zero, nature positive, healthier planet. Rachel has worked in policy and government affairs roles across the pharmaceutical sector for over 10 years, and has previously worked on environmental policy, including in the European parliament and in the water sector.
Future Biogas
Chief Executive Officer
Philipp Lukas is the founder and CEO of Future Biogas – one of the largest producers of biomethane in the UK.
Following investment from 3i Infrastructure plc, Future Biogas is working to reshape the biogas industry, directly decarbonising agriculture and industry by making high-quality, unsubsidised green gas from sustainably grown inputs.
Philipp sits on the board of the European Biogas Association (EBA) and co-chairs the EU Commission’s Biomethane Industrial Partnership (BIP).
Manufacture 2030
Commercial Director
As Manufacture 2030’s Commercial Director, Cassandra (Cass) helps businesses understand how to start, or build on their Scope 3 journey through M2030’s industry-aligned supplier engagement, designed to reduce environmental impacts at scale. Cass launched M2030’s Activate program at COP27, in 2022, aiming to tackle Active Pharmaceutical Ingredients supply chain; an well-known hotspot of emissions. Now in entering its third phase, the scale and impact of Activate continues to grow through collaboration with buying organisations, suppliers and partnerships. Cass will share best practice and learnings from Activate and the other programs M2030 delivers in the Pharmaceutical and Consumer Health industries.
AstraZeneca & PSCI
Senior Director, Sustainable Procurement & Chair
As Senior Director of Sustainable Procurement in the Global Procurement team at AstraZeneca, Rob is accountable for delivery of AstraZeneca’s sustainability goals through their supply chain. He partners with Group Sustainability to deliver the corporate sustainability objectives, developing supply chain performance against environmental and social sustainability goals. He also works cross[1]functionally with teams from R&D, Operations, Commercial and Corporate Communications to
engage with AstraZeneca’s employees, suppliers and customers.
Rob has over 25 years’ experience in technical, commercial and leadership roles across a range of industry sectors, from mining and renewable electricity to telecoms and pharmaceuticals. The thread connecting this career path downstream from the ‘coal face’ is energy, which is Rob’s specialist subject.
After starting his career in technical roles in an SME land development company in the UK (mining, waste disposal, land remediation, property) he co-led the founding of a renewable energy development subsidiary, specialising in wind farms. In 2010, Rob moved to British Telecommunications plc to lead delivery of their renewable energy goals, decarbonising the operations of one of the UK’s largest electricity consumers. In 2021, Rob moved to AstraZeneca when a new position was created to lead Scope 3 decarbonisation as part of AstraZeneca’s Ambition Zero Carbon programme.
In addition to his role at AstraZeneca, Rob is also a lecturer in Energy Procurement for the Energy Institute and is an Advisory Board member of the Durham Energy Institute at Durham University. Rob holds an MSc in Engineering Hydrology from Newcastle University and a BSc (Hons) in Applied Geology from the University of Leicester. He is also a graduate of the WBCSD Sustainability Leaders course, provided in conjunction with Yale University and the University of Lancaster.
Regulations and roadmaps like “Design for Life” are driving efforts to improve waste management and circularity in healthcare, but how can these be effectively operationalised? Can we mix high-tech innovations and simple, behaviour-driven solutions to tackle recycling challenges?
Honeywell & CiPPPA
Global Sustainability Lead, Chairman
Duncan leads the vision and execution of Honeywell’s sustainability goals around Aclar, Solstice Air, and healthcare packaging.
He has worked for 15 years in the pharmaceutical packaging industry and in recent years, has delivered unique sustainability solutions to the UK market, helping to advance circularity around difficult-to-recycle healthcare packaging materials.
He is a founding alumnus of the Sustainable Medicines Partnership and a founder and Chairman of the Circularity in Primary Pharmaceutical Packaging Accelerator (CiPPPA), a not-for-profit, pre-competitive action collaborative focused on the alignment of sustainable activities within the pharmaceutical industry, enabling the reduction, collection, and recycling of pharmaceutical packaging associated with blister packs, metered dose inhalers and auto injectors.
Bayer
Head of Sustainability & Public Affairs UK & Ireland
Andy spent 17 years in senior Sales leadership and Commercial roles within FMCG, Skincare and Pharma, he then made a career pivot over 3 years ago to proactively supercharge and lead the Sustainability agenda at Bayer UK & Ireland. Andy works across the full spectrum of Sustainability, covering Policy, ESG & Non-Financial Disclosures, Carbon Footprinting, Impact Valuation, Life Cycle Assessments, Employee Engagement and many more.
Andy voices how driving a culture of sustainability and incorporating it into everyday roles and responsibilities is essential to delivering a net zero agenda as well as the powerful role story telling plays in supporting organisations transformation from Board level all the way through the business.
Scottish Government Health & IoD Scotland
Head of Circular Economy Programme & IoD Scotland Lead Sustainability Ambassador
EN:ABLE Sustainability
Sustainable Innovation Consultant
I came to sustainability as an undergraduate industrial design student, where the opportunities for innovation that it presented, totally inspired me, and set the course for my working life.
After a relatively short stint as an industrial design consultant, and a bout of travel, I took on/fell into a PhD in sustainable design with Electrolux at Cranfield University, and I’ve been working in Sustainable Innovation ever since. I’ve taught thousands of undergraduate and postgrad design students to consider sustainability in all that they create, giving them the tools to make a meaningful difference.
I have also consistently worked with companies and organisation to show them how to think, adapt and operate with sustainability in mind, using my experience to bridge their knowledge gaps and enable the transition. My ethos is very much around making things happen in real time, creating change through practical action.
Medicines and Healthcare products Regulatory Agency (MHRA)
Head of Standards and Regulatory Governance, Secretary, Scientific Director of the BP Commission
Steve Hoare is responsible for the British Pharmacopoeia, which sets the minimum standards for Quality for medicines marketed in the UK (and recognised in over 100 countries) , and is supporting the MHRA in the development of its Sustainability Policy. An analytical chemist by training, Steve has a background in Quality roles in the pharmaceutical industry, most recently a policy director for a biopharmaceutical trade association, leading on both regulation and sustainability. Steve is active in the development of international approaches to sustainability in standards setting.
How are science-based sustainability metrics driving measurable change? Join us as we explore real-world tools, metrics, and methodologies that are making an impact today, providing practical insights into the opportunities and challenges of applying sustainability metrics in real contexts.
YewMaker & AstraZeneca
Chief Executive Officer & NED
Nazneen is a scientist, doctor, entrepreneur, and non-executive director. She is Founder and CEO of YewMaker, which creates science-based sustainable healthcare solutions, including MCF Classifier – a medicines carbon footprint solution. YewMaker leads the Sustainable Medicines Partnership, a not-for-profit collaboration of 48 organisations working to reduce the waste of medicines and from medicines.
Nazneen is a Non-Executive Director at AstraZeneca, where she chairs the Sustainability Committee and is a member of the Science, Remuneration, and Nomination Committees. Nazneen is an internationally-recognised expert in cancer genomics and was previously Professor of Human Genetics and Head of Cancer Genetics at the Royal Marsden NHS Foundation Trust and Institute of Cancer Research
Johnson & Johnson Innovative Medicine
Director, Innovative Health - Environmental Sustainability in Clinical Research
Jason has over 20 years of experience working in Pharma, 16 years of which have been with Johnson & Johnson Innovative Medicine. For the last 8 years, he has been a member of their Innovative Health team where he applies his strong technical and collaboration skills and global project leadership in delivering transformational innovation projects that have the goal to shape the future of clinical trial operations at Johnson & Johnson. Jason is Director of Environmental Sustainability in Clinical Research where he is leading the transformation of Johnson & Johnson Innovative Medicine’s global clinical operations towards sustainability. He is also co-founder and work package lead for the Horizons Europe funded Digital Health in the Circular Economy project, and a member of the Sustainable Design Engineering faculty at Delft University of Technology.
Lonza
Senior Director, Head of Global Process Technology & Innovation, Small Molecules
Dr. Niklaus Künzle is Senior Director, Head of Global Process Technology & Innovation for Small Molecules at Lonza. He is responsible for development & implementation of technologies and methodologies in the field of Sustainability, Process Analytics (PAT), Solid Particle Engineering, Thermal Separation and Digitalization. Furthermore he is responsible for Lonza’s Small Molecules Sustainability Strategy
He earned his Ph.D. in Chemical Engineering at the Swiss Federal Institute of Technology (ETH Zürich, 2002) and subsequently worked in several technical and management functions in Lonza R&D and operations organization.
Dr. Künzle has 20+ years experience in specialty ingredients and pharmaceutical manufacturing industry.
Throughout his career, Niklaus Künzle has worked across a broad portfolio of manufacturing technologies applied on small scale up to commercial multipurpose and continuous world scale.
Access to Medicine Foundation
Director of Operations | interim Director of Government Engagement and Policy
Marijn Verhoef is Director of Operations at the Foundation. Marijn oversees implementation of strategy, tracking of the Foundation’s progress and internal alignment. Furthermore, he is the interim Director of Government Engagement & Policy. In that role, he liaises with governments, private foundations and multilateral organisations that are actively working to improve global health and access to medicine. He also oversees the Foundation’s fundraising activities. Prior to assuming this role, he was the Director of Research, where he led the research team, steered key initiatives, and drove high-quality research outcomes that contributed to impactful change.
Marijn is a pharmacist by training, holding a Master’s degree in Pharmaceutical Sciences from Utrecht University in the Netherlands, where he completed a thesis on medication-related hospital admissions.
Before joining the Foundation, Marijn spent more than 5 years working in marketing and medical affairs in a multinational pharmaceutical company in roles relating to immunology and infectious diseases. Marijn worked at the Foundation as a Researcher, before heading the Company Engagement team for four years. Before taking on this role, he was the Director of Research.
Revolutionize the future of medicine with eco-innovative design, paving the way to a zero-carbon footprint. Join us to lead the charge in sustainable pharmaceutical breakthroughs.
Ajinomoto Bio-Pharma Services
Strategic Marketing Manager
After a study as engineer in environmental technologies, I started my career in an environmental agency with a clear vision on a sustainable industry serving our society. Since then I’ve worked as environmental and safety manager in the chemical/pharma industry, continuously improving the SHE management systems.
Since 2018 I have the opportunity to support our CDMO business even closer in its mission to help improve the health of humankind. Through innovation, compliance, continuous improvement, communication and teamwork, we do our part to make the world a better place by resolving issues of health and well-being, food resources and global sustainability.
The Ajinomoto group recognizes Climate Change a significant issue, and is committed to reduce its emissions with 50% by 2030. also within Ajinomoto Omnichem we are as a team structuring our strategic transition to a climate neutral CDMO .
As this is close to my values, I’m a co-founder of Claire (www.claire-co2.com) which is a platform for local CO2 compensation. This enables our local industrial ecosystem to give an answer to the aspiration of climate neutral supply chain of many big corporations, while doing good for your own neighbourhood.
Innovate UK
Deputy Challenge Director – Medicines Manufacturing Challenge
Mark Talford has over 20 years of experience in research and innovation posts in industry and academia. Beginning his career as a lecturer in Chemical Engineering at the University of Bradford, Mark joined BNFL, and later British Nuclear Group, Sellafield following the closure of Bradford’s original course. As a Senior Technical Advisor to the Waste Vitrification Plants Mark was responsible for the delivery of a multi-million-pound annual programme of process improvement research from both UK and overseas contractors.
In 2006 Mark joined Britest Ltd, becoming Technical Director in 2012 and CEO in 2018. At Britest Mark was involved in the scoping and delivery of several pharma, speciality and fine chemicals collaborative innovation projects including the EU F3 Factory and SYNFLOW programmes and the UK AMSCI ReMediES and ADDoPT projects, as well as supporting a variety of pharma and non-pharma MNC’s and CDMOs develop and implement novel primary and secondary manufacturing processes using the Britest process understanding toolkit. He joined the UKRI Medicines Manufacturing Industrial Strategy Challenge Fund Team as Deputy Challenge Director in February 2021.
A chartered Chemical Engineer, Mark holds a degree in Chemical Engineering and a PhD in polymer process modelling from the University of Bradford.
AstraZeneca
Principal Scientist, Sustainability, Chemical Development
Steve Swallow is a Principal Scientist in Sustainability at AstraZeneca’s Chemical Development department in Macclesfield, leading efforts to develop eco-friendly chemical processes and reduce environmental impact. He began his academic journey with a PhD in organic synthesis from the University of Sheffield, followed by a SERC/NATO fellowship at the University of Colorado Boulder.
In the early stages of his career, Steve made significant contributions as a medicinal chemist at Roche in both the UK and the US, where he led drug discovery programs targeting antivirals, particularly HIV and HCV. In 2004, he joined AstraZeneca, where he expanded his focus beyond medicinal chemistry to tackle interdisciplinary challenges in chemistry and toxicology within Global Safety Assessment.
Since joining Chemical Development in 2015, Steve has held various leadership roles across multiple teams. Currently, he spearheads sustainability initiatives at AstraZeneca, advancing the sustainability agenda through strong internal collaboration and strategic partnerships with industry and academic institutions.
Medicines Manufacturing Innovation Centre, CPI
Head of Sustainability (Pharma),
Deborah joined the Medicines Manufacturing Innovation Centre, part of CPI, in 2022. She is currently the Head of Sustainability (Pharma), leading CPI’s Pharma sustainability initiatives, having held a previous role at CPI as a Grand Challenge lead, responsible for the advancement of technological innovation around continuous manufacturing within the centre.
With ~ 20 years’ experience in the pharmaceutical industry (Q-One BIOTECH Ltd, Piramal Pharma, Bioreliance, Merck), she has held various roles. From QA to Development Scientist, advancing to Head of Research and Development for a CRO/CMO specialising in Antibody Drug Conjugates. She has also held commercial roles, both within Business development and leading the Strategic Program Management team to ensure successful partnerships. Deborah has extensive CMC experience from proof-of-concept development to commercialising drug products, leading large skilled teams.
Deborah graduated with a BSc (Hons) in Biochemistry and Molecular Biology as well as a PhD in Glycobiology, both from the University of Strathclyde, Glasgow.
How can sustainability training be embedded into company culture, guiding suppliers and teams toward sustainable solutions? What actions are promoting diversity and inclusion in pharma to ensure its future? How does the sustainability agenda attract early career talent, and in what ways are apprenticeships contributing to tackling sustainability challenges?
AstraZeneca UK
HR Director
Phoebe is the HR Director for AstraZeneca UK, where she champions sustainable practices in people management and organisational development. With an innate curiosity and creativity, Phoebe is dedicated to fostering an inclusive and sustainable workplace culture. She has over 15 years of experience leading People & Organisation agendas, working in the US, Netherlands, Italy, and the UK across various industries, which has equipped her with a global perspective on sustainable business practices.
Phoebe holds an undergraduate degree in Poetry from Colorado College and a Masters in Public Administration from Cornell University. She resides in Cambridge with her husband and three children. In her personal time, she enjoys traveling, cooking, running, cycling, gardening, and reading.
RoslinCT
Head of Sustainability
Adam started his professional career as a chemist, later diversifying into environmental protection focusing on waste management, producer responsibility, and transfrontier shipments of waste. Adam then spent 10 years in consultancy, advising private and public sector clients on strategic and technical application of resource efficiency and the circular economy, before developing and leading corporate sustainability strategies focused on delivering real impact for people and the planet. Adam is an alumnus of the University of Edinburgh and an active member of numerous local, national and global sustainability working groups. He has presented at various conferences and events including COP26, providing global representation for his employers. Adam is a Chartered Waste Manager and accredited Project Manager, a keen cyclist, a father of two boys, and lives in Portobello in Edinburgh.
AstraZeneca
Sustainability Project Manager Apprentice
Elishia Alleyne is a Sustainability Project Manager Apprentice at AstraZeneca, based in Macclesfield. Elishia has actively engaged in numerous sustainability projects and initiatives within the organization, demonstrating a robust background in sustainability and corporate responsibility.
Elishia is also deeply committed to youth advocacy and mental health, having participated as a speaker and ambassador at the One Young World Summit. Elishia is dedicated to promoting ethical practices, transparency, and social impact in professional endeavors.
In the role at AstraZeneca, Elishia is involved in project and change management, driving social and environmental change objectives within the Global Sustainability department. Elishia’s professional background includes experience in Corporate Responsibility & Sustainability.
Elishia is currently pursuing a degree in Project Management at Northeastern University London while working full-time. Elishia is a strong advocate for youth-centered design and empowerment, actively participating in youth advocacy. Through this work, Elishia is able to influence local policy and champions gender equality and children’s rights.
DHL Supply Chain
UKI Sustainability Manager
Logistics and Supply Chain Manager with ~20 years of management experience across Supply Chain and International forwarding in areas such as sustainability, operations, environmental & waste management, customer service, account management and account development.
I am currently UKI Sustainability Manager at DHL Supply Chain; the world’s largest logistics company; supporting with the development and increasing delivery of Green Solutions across the UK & Ireland operations.
Lloyds Banking Group
Head of Social Sustainability
Beth Knight is a leading figure in social impact and sustainability. With over 15 years of experience in leadership roles at major companies including Lloyds Banking Group, Amazon, and EY. Beth also holds non-executive positions with the British Tourism Authority and Save the Children and is a Senior Associate at the University of Cambridge Institute of Sustainability Leadership.
Beth’s expertise extends to sustainability standards with advisory roles on GRI, CSRD, and TISFD working groups. She has also played a crucial role in increasing diversity within the sustainability sector by launching a UK apprenticeship program. Recognized for her contributions, Beth was named the Great British Businesswoman of the Year in 2022/23. Her work during the COVID-19 pandemic and humanitarian aid response to the war in Ukraine has further solidified her reputation as an innovator in social impact.
What can we learn from work on care pathways? How can taking a care pathways approach allow us to evaluate environmental impact from a systems perspective, and redefine what we mean by value? What is the critical role of collaboration in driving progress? Once innovative medicines address challenges, how can we ensure they reach patients? How are we developing the skills needed for future system changes?
Sustainable Healthcare Coalition
Chair
As a leading expert in sustainability and health, I currently serve as Chair of the Sustainable Healthcare Coalition a pioneering organisation that brings together partners to advance sustainable healthcare.
Additionally, I act as an independent expert advisor and board member for various national and global organisations, providing valuable insight and guidance on well-being and sustainability.
I’m passionate about reframing thinking and have a track record of developing innovative strategies and programmes at the heart of business and government.
My background includes senior roles in the UK Government as Deputy Chief Medical Officer and Director General, in the World Health Organisation as Director of Chronic Disease and Health Promotion, and in the private sector, as Bupa’s Chief Wellbeing Officer and as a Director in PwC’s health and sustainability teams.
I am a visiting Professor at UCL and a Senior Associate at Cambridge Institute for Sustainability Leadership and have served on various boards including British Land’s Sustainability Advisory Panel, Marks and Spencer’s Sustainable Retail Advisory Board, and Business in the Community’s Wellbeing Leadership Team.
QEUH, Glasgow & Centre for Sustainable Delivery (Scotland)
Renal Consultant & Green Renal Clinical Lead
Dr Eleanor Murray MBChB, MD, MRCP; Renal Consultant, QEUH, Glasgow and Green Renal Clinical Lead Centre for Sustainable Delivery (Scotland)
I set up a sustainability committee within my Renal Department whilst a trainee working in Glasgow. I also proposed a ‘sustainability scholarship’ which RCPSG and Scottish Government agreed to jointly fund; this allowed me to focus on healthcare sustainability for one day a week during the last year of my training. I focussed on education, including collaborating with the Centre for Sustainable Healthcare to develop a course on Sustainable Kidney Care.
I now have a Consultant post, remain involved in Greater Glasgow and Clyde Sustainability committee, as well as the other initiatives outlined. We have implemented a number of QI projects, made efforts to estimate our emission reductions, and to disseminate the results. I have forged links with the University of Glasgow, and supported students and trainees undertaking their own SusQI projects.
I am active in the UK Kidney Association Sustainable Kidney Care Group; I co-lead the renal Atlas of Variation workstream to facilitate benchmarking of progress towards Net Zero. Considering that prevention is a critical component of any plan to achieve a Net Zero NHS, I have also been involved in a working group to develop a Chronic Kidney Disease (CKD) Action Plan. This has been presented to Scottish Government to highlight a growing issue. The Scottish Renal Association advocate for environmentally sustainable change, through our QI group, annual conferences, and efforts to incorporate sustainability into the Renal Registry Report.
Finally, I now act as clinical lead for the Green Renal Project, following on from the successes of the National Green Theatre Project. Renal is a relatively small specialty, but one with a large and expanding CKD population, compounded by the huge carbon intensity of dialysis. A reasonable evidence base exists, and I intend to build on this whilst delivering environmentally beneficial change across Scotland.
Faculty of Pharmaceutical Medicine & Reinventing Health
President & CMO
Dr Sheuli Porkess is an experienced pharmaceutical physician, specialising in medical affairs, digital health & AI and life sciences policy and within the UK and internationally. Sheuli is the President of the Faculty of Pharmaceutical Medicine, CMO and Reinventing Health and Director of Actaros Consultancy and holds a number of other advisory roles.
Prior to this Sheuli has held medical leadership roles in companies nationally, regionally and globally. Sheuli is also the former Director of Research, Medical and Innovation at the Association of the British Pharmaceutical Industry.
Sheuli is a Fellow of the Faculty of Pharmaceutical Medicine, a Global Fellow in Medicine Development with IFAPP and a Fellow of the Royal College of Physicians of London.
PwC
Senior Manager, Sustainability Strategy
Callum specialises in the delivery of sustainability best practices for health science organisations globally as part of PwC’s Sustainability Strategy team. His experience includes the translation of system-wide requirements with practical sustainability interventions, the implementation of costed transition plans, and the development of business cases for operational and supply chain change. It’s Callum’s strongly held belief that the collaborative and innovative approaches required to achieve today’s sustainability goals will ultimately be what drives the sector’s success into the future.
AstraZeneca
Director of Epidemiology, BioMedical Pharmaceuticals
Ekaterina is a Director of Epidemiology at AstraZeneca, where she is responsible for evidence strategy and delivery for part of the respiratory portfolio. Ekaterina trained as an epidemiologist at Harvard School of Public Health and has over 15 years of experience in epidemiological research and public health across academia, government, and industry. For the past 4 years, Ekaterina has lead evidence generation on the environmental impact of asthma care pathways as part of the CARBON program and supporting wider capability build initiatives across AstraZeneca. More recently, she has co-led the development of CARESA, a modelling tool to quantify the environmental impact of care pathways. Ekaterina is interested in how care delivery impacts environmental sustainability, and how we (re)-design healthcare systems for the future that deliver for the patients and the planet.
There is a fine balance between genuine sustainability efforts and greenwashing. Can new “green laws” help celebrate real progress while ensuring companies back their sustainability claims with solid data? Join us to discuss sustainability practises across the sector.
UCL & Real Zero
Professor Intensive Care Medicine & Co-founder
Intensive Care clinician. Director UCL Centre for Human Health and Performance, with >550 papers (8 in Nature, inc first description of a ‘gene for human performance’.)
Extensive work in Climate Change. Founder https://realzero.earth/
Consults in medtech (inc previously for Google Health/ Deepmind) and pharma (lately vaccines).
Board, Silver Creek Ltd
ex-Board Chair ed-tech: Obrizum https://www.obrizum.com/
5 charity boards
22 years leader in health and climate change (chair 27-country Lancet Countdown)
Founder and Board, ‘Real Zero Ltd’ (non-profit action on climate change)
Award winning author (2 x childrens’ books, 1 x thriller) and script editor.
Public speaker (>600 invited lectures to public, business, medicine and science) fronting >6 TV shows, inc 5 Royal Institution Xmas Lectures 2007)- https://londonspeakerbureau.com/speaker-profile/hugh-montgomery/
CMS CAMERON MCKENNA NABARRO OLSWANG LLP
UK Head of Advertising and Marketing, Of Counsel (IP Team)
Stuart Helmer is Of Counsel in the Intellectual Property team and head of the CMS London advertising and marketing group. He has over 15 years’ experience of advising a wide range of businesses on advertising and marketing compliance and disputes and is individually ranked for Advertising and Marketing by Chambers. Clients describe him as ”bloody fantastic … really, really pragmatic and an absolute lifesaver”.
Stuart frequently advises on comparative advertising disputes, including in major High Court litigation in relation to allegedly misleading comparative advertising. He also frequently advises on making and responding to complaints to the Advertising Standards Authority, where he has particular experience of late-stage interventions to reverse or mitigate a draft decision against his client. He also has extensive experience of implementing and operating day-to-day advertising clearance programmes.
My Green Lab
Technical Program Director
Pernilla Sörme was born in Sweden but now lives in the UK. At My Green Lab, she serves as the project lead to continually update and improve the My Green Lab Certification Program. She also develops the technical resources and research to support green lab best practices as well as program support in the implementation of the My Green Lab program across the industry. Previous to this she was with AstraZeneca for 19 years. After completing her PhD in Medicinal chemistry at Lund’s University, she worked for more than 10 years in the chemistry labs at AstraZeneca with designing and developing new medicine. She then took up a position at AstraZeneca’s global sustainability function where she, among other things, worked with environmental risk for new medicines and safe discharge for the operations sites but then moved on to work with her true passion for environmental sustainability in the labs. She started up the global green labs project at AstraZeneca and during a four-year period, expanded the project to include all labs in the R&D and PTD sites.
University of York
Research Professor, Environment and Geography
I am a research professor at the University of York focused on sustainable healthcare and pollution management; I am a member of the York Environmental Sustainability Institute (YESI) Steering Group. Previously, I played a pivotal role in advancing the environmental and health research, innovation, and global engagement agenda working at AstraZeneca where I was the Global Head of Environmental Protection and a member of its Global Sustainability and UK Leadership Teams. I have had strategic coordination and leadership roles for the European pharmaceutical industry trade association (Efpia), AMR Industry Alliance, Federation of European Chemical Industry Associations (CEFIC) and the UKRIs Natural Environment Research Council (NERC). I have built collaborations with business, industry, government agencies and third sector organisations to enhance the uptake and application of research in environmental- and health-based policy and business best practice; my research has shaped environmental policy and regulation on several fronts. I seek to drive innovation and systems-level thinking to tackle some of the critical challenges we are facing. My research areas include: (i) addressing the environmental impact of human medicinal products; (ii) understanding the importance of the environmental dimension of antimicrobial resistance (AMR) and the effectiveness of proposed environmental stewardship and mitigation measures; (iii) determining minimum selective concentrations for antibiotic resistance, co-selective agents and environmentally relevant mixtures; (iv) ensuring that access to medicines initiatives to address health inequity in low- and middle-income countries is environmentally sustainable; especially initiatives to address gender inequality; (v) determining the impact of climate change on public health and environmental pollution management; (vi) integrating the climate and wider environmental footprint of medicinal products and associated care into the patient benefit-cost assessments to deliver patient centric net zero healthcare; and (vii) using metagenomic and machine learning approaches to assess the persistence, biodegradation and mobility of chemicals earlier in safe and sustainable product development.
SAS
Senior Industry Consultant, Global Health and Life Sciences Customer Advisory
Lisa is part of the Healthcare & Life Sciences customer advisory team at SAS Institute, where she helps life sciences companies use analytics software across all areas of drug development and commercialization. She has a background in data analytics and consulting at companies such as IQVIA and BCG.
Lisa is a spearhead of sustainability work at SAS Institute, exploring novel ways to apply advanced machine learning, AI and decision intelligence to ESG reporting and decarbonisation and embed sustainability throughout operations.
AstraZeneca UK
Chair
Shaun Grady is responsible for representing AstraZeneca’s whole enterprise across the UK. In this role, reporting to CEO Pascal Soriot, Shaun works closely with relevant senior leaders across AstraZeneca to champion and support our science and R&D function, operations and manufacturing, commercial business, and our corporate priorities across the life sciences ecosystem in the UK. Shaun also manages critical relationships with senior Government representatives, business leaders and industry associations, as well as leading on advocacy for key policy priorities. As UK Chair he also represents AstraZeneca’s global enterprise, where we support and leverage the UK’s unique diplomatic and economic networks to improve trade and international cooperation in life sciences. Additionally, Shaun chairs the UK Leadership Team, the UK Employee Forum and the UK Inclusion and Diversity working group. Before becoming the Chair of AstraZeneca UK, Shaun led the company’s business development function where he has worked for over 20 years, and before that was a member of the legal team working on corporate transactions. Shaun has played a central role in almost every major business development activity during his time with the company, including the merger of Astra and Zeneca, the acquisition of Cambridge Antibody Technology (CAT), and later MedImmune and Amylin, and the buy-out of Bristol-Myers’ Squibb’s interest in the AstraZeneca-BMS Diabetes Alliance. More recently, Shaun led the transaction team for AstraZeneca’s global ADC collaborations with Daichi Sankyo, and the acquisition of Gracell, Icosovax and Fusion, as well as the collaboration with Ecogene. Shaun is a Board member at the BioIndustry Association (BIA) and CBI President’s Committee, is Chairman of the Board of Directors of Cambridge United Football Club, and a Board member at Cambridge Arts Theatre, and at Prostate Cancer Research, as well as an Honorary Fellow at The University of Cambridge Judge Business School and Lucy Cavendish College Cambridge.
The Discovery Centre (DISC)
A state-of-the-art global R&D facility located in the heart of the Cambridge Biomedical Campus.
Cambridge, one of the most exciting bioscience hotspots in the world, is home to the largest UK research and development centre – The DISC. Here more than 2,300 scientists work in drug discovery and development, across our therapy areas, each playing a central role in our mission to deliver life-changing medicines to patients. The DISC is uniquely designed to strengthen collaboration, promote openness, and improve the sustainability of every aspect of our science and our business operations.
The DISC is a 12 – minute bus ride from Cambridge Railway Station.
Biomedical Campus, 1 Francis Crick Ave, Trumpington, Cambridge CB2 0AA
